Medium materiality5/10
Morgan Stanley Downgrades Halozyme to Equalweight
Why it may matterVerify against the original reporting
The downgrade is a modest negative signal, though the target still implies upside from the posted price.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Morgan Stanley downgraded HALO to Equalweight. Its $109 target is about 6% above the posted price of $102.98, tempering the bearish implication of the downgrade.
- Morgan Stanley cut HALO to Equalweight; its $109 target is above the posted $102.98 price.
Key facts
- 01
Target: $109
- 02
Posted price: $102.98
- 03
Analyst firm: Morgan Stanley
- 04
Analyst: Sean Laaman
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.